RxDoctor Payments Data

Manpreet Chawla

Adult Health · Egg Harbor Township, NJNPI 1710445333

Payments from drug & device makers

$1,358in general payments, 2019–2025

Across 57 payments — averaging $23.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$248
  • Novo Nordisk$223
  • AstraZeneca$125
  • Abbott$114
  • AbbVie$110
  • Tandem Diabetes Care, Inc.$102
  • plus $437 from 13 others

What the payments were for

  • Food & beverage$1,358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,358 in reported general payments places this provider in the 75th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$39,256
Medicare patients
232
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$144,179
MounjaroTirzepatide66$109,792
JardianceEmpagliflozin63$90,790
TrulicityDulaglutide31$67,898
FarxigaDapagliflozin Propanediol28$40,990
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$25,895
Bydureon BciseExenatide Microspheres21$21,329
JanuviaSitagliptin Phosphate21$19,888
Tresiba Flextouch U-200Insulin Degludec14$18,224
Tresiba Flextouch U-100Insulin Degludec23$17,914
Humalog Kwikpen U-100Insulin Lispro43$16,966
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$10,871
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$8,675
Novolog FlexpenInsulin Aspart28$8,306
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$35$181,683111 claims
Novo NordiskOzempic$223$144,17996 claims
AstraZenecaFarxiga$125$40,99028 claims
AbbVieSynthroid$110$3,28333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Egg Harbor Township

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →